Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||fibrous histiocytoma||not applicable||Pembrolizumab||Phase II||Actionable||In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in complete response in 10% (1/10) and partial response in 30% (3/10) of patients with undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) (J Clin Oncol 35, 2017 (suppl; abstr 11008)).||detail...|
|PubMed Id||Reference Title||Details|
|Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.||Full reference...|